Data from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer

<div>Abstract<p>Men with circulating tumor cell (CTC) AR-V7–positive metastatic castration-resistant prostate cancer (mCRPC) have worse outcomes when treated with enzalutamide/abiraterone. However, most men lack CTC AR-V7 detection, and additional predictive biomarkers are needed. We conducted a retrospective secondary analysis of the prospective PROPHECY trial (NCT02269982) of men with mCRPC undergoing treatment with enzalutamide/abiraterone, analyzing pooled CTC and germline DNA for whole-genome copy-number alterations (CNA) in 73 samples from 48 men over time along with pooled CTC and germline whole-exome sequencing on 22 paired samples before and following progression on androgen receptor (AR) inhibitor therapy to identify somatic genomic alterations associated with acquired resistance. We observed broad interpatient and longitudinal CTC genomic heterogeneity from AR-V7–negative men with mCRPC, including common gains of <i>KDM6A, MYCN</i>, and <i>AR</i>, and loss of <i>ZFHX3, BRCA1</i>, and <i>PTEN</i>. Men who had progression-free survival of ≤3 months despite enzalutamide/abiraterone treatment were more likely to have baseline CTC genomic loss of <i>CHD1, PTEN, PHLPP1</i>, and <i>ZFHX3</i> and gains of <i>BRCA2, KDM5D, MYCN</i>, and <i>SPARC</i>. After progression on abiraterone/enzalutamide, we observed clonal evolution of CTCs harboring <i>TP53</i> mutations and gain of <i>ATM, KDM6A</i>, and <i>MYC</i>, and loss of <i>NCOR1, PTEN, RB1</i>, and <i>RUNX2</i>. CTC genomic findings were independently confirmed in a separate cohort of mCRPC men who progressed despite prior treatment with abiraterone/enzalutamide (NCT02204943).</p>Implications:<p>We identified common and reproducible genomic alterations in CTCs from AR-V7–negative mCRPC men associated with poor outcomes during enzalutamide/abiraterone treatment, including CNAs in genes linked to lineage plasticity and epigenetic signaling, DNA repair, AR, TP53/RB1, PTEN, and WNT pathways.</p></div>

Duke Scholars

Author Susan Halabi Biostatistics & Bioinformatics, Division of Biostatistics

Author Andrew John Armstrong Medicine, Medical Oncology